Patents by Inventor Martin Harvey
Martin Harvey has filed for patents to protect the following inventions. This listing includes patent applications that are pending as well as patents that have already been granted by the United States Patent and Trademark Office (USPTO).
-
Patent number: 11939321Abstract: The invention provides a compound of formula (0): or a pharmaceutically acceptable salt, N-oxide or tautomer thereof; wherein: n is 1 or 2; X is CH or N; Y is selected from CH and C—F; Z is selected from C—Rz and N; R1 is selected from: -(Alk1)t-Cyc1; wherein t is 0 or 1; Optionally substituted C1-6 acyclic hydrocarbon groups R2 is selected from hydrogen; halogen; and C1-3 hydrocarbon groups optionally substituted with one or more fluorine atoms; R3 is hydrogen or a group L1-R7; R4 is selected from hydrogen; methoxy; and optionally substituted C1-3 alkyl; and R4a is selected from hydrogen and a C1-3 alkyl group; wherein Rz, Alk1, Cyc1, L1 and R7 are defined herein; provided that the compound is other than 6-benzyl-3-{2-[(2-methylpyrimidin-4-yl)amino]pyridin-4-yl}-7,8-dihydro-1,6-naphthyridin-5(6H)-one and 3-{2-[(2-methylpyrimidin-4-yl)amino]pyridin-4-yl}-7,8-dihydro-1,6-naphthyridin-5(6H)-one and salts and tautomers thereof.Type: GrantFiled: April 7, 2021Date of Patent: March 26, 2024Assignee: OTSUKA PHARMACEUTICAL CO., LTD.Inventors: Valerio Berdini, Ildiko Maria Buck, James Edward Harvey Day, Charlotte Mary Griffiths-Jones, Thomas Daniel Heightman, Steven Howard, Christopher William Murray, David Norton, Marc O'Reilly, Alison Jo-Anne Woolford, Michael Liam Cooke, David Cousin, Stuart Thomas Onions, Jonathan Martin Shannon, John Paul Watts
-
Publication number: 20230357208Abstract: The present disclosure provides compounds, pharmaceutically acceptable compositions thereof, and methods of using the same.Type: ApplicationFiled: February 16, 2023Publication date: November 9, 2023Applicant: Epizyme, Inc.Inventors: Darren Martin Harvey, John Emmerson Campbell, Kenneth William Duncan
-
Patent number: 11685732Abstract: The present disclosure provides compounds, pharmaceutically acceptable compositions thereof, and methods of using the same.Type: GrantFiled: November 29, 2018Date of Patent: June 27, 2023Assignee: Epizyme, Inc.Inventors: Darren Martin Harvey, John Emmerson Campbell, Kenneth William Duncan
-
Publication number: 20230101819Abstract: The present disclosure provides carboxamides and sulfonamides having Formula (I); and the pharmaceutically acceptable salts and solvates thereof, wherein A, Y, B, X, and Z are defined as set forth in the specification. The present disclosure is also directed to the use of compounds of Formula (I) to treat a disorder responsive to the blockade of SMYD proteins such as SMYD3 or SMYD2. Compounds of the present disclosure are especially useful for treating cancer.Type: ApplicationFiled: November 22, 2021Publication date: March 30, 2023Inventors: Megan Alene Cloonan FOLEY, Kevin Wayne KUNTZ, James Edward John MILLS, Lorna Helen MITCHELL, Michael John MUNCHHOF, Darren Martin HARVEY
-
Publication number: 20230075198Abstract: The present disclosure provides substituted indole compounds of Formula I: (I) and the pharmaceutically acceptable salts and solvates thereof, wherein R1a, R1e, G1, G2, Q1, Q2, Q3, and (II) are defined as set forth in the specification. The present disclosure is also directed to the use of compounds of Formula I to treat a disease, disorder, or condition such as cancer in a subject.Type: ApplicationFiled: August 14, 2019Publication date: March 9, 2023Inventors: John LAMPE, John CAMPBELL, Kenneth DUNCAN, Megan Alene Cloonan FOLEY, Darren Martin HARVEY, Michael John MUNCHHOF, Michael THOMENIUS, Lawrence Alan REITER
-
Publication number: 20230046656Abstract: The present disclosure provides novel cancer therapies. The treatment of cancers harboring EP300 mutations with CREBBP inhibition therapy is described.Type: ApplicationFiled: February 9, 2022Publication date: February 16, 2023Applicant: Epizyme, Inc.Inventors: Alexandra Grassian, Scott Ribich, Jesse Smith, Darren Martin Harvey
-
Publication number: 20220356174Abstract: This disclosure generally relates to pyridine-2-one compounds of formula (I) and methods of using them in the treatment of a disorder, such as cancer or a SMARCA2-associated disorder, including as antagonists (e.g., inhibitors) of SMARCA2. The present disclosure provides treatment modalities, e.g., strategies, treatment methods, patient stratification methods, compounds, combinations, and compositions that are useful for the treatment of disorders, e.g., proliferative disorders, such as certain cancers. Some aspects of this disclosure provide treatment modalities, methods, strategies, compounds, compositions, combinations, and dosage forms for the treatment of cell proliferative disorders, e.g., cancers with decreased activity or function, or loss of function, of SMARCA4 with a SMARCA2 antagonist.Type: ApplicationFiled: July 24, 2019Publication date: November 10, 2022Applicant: Epizyme, Inc.Inventors: Oscar Moradei, John W. Lampe, Darren Martin Harvey, John Emmerson Campbell, Kenneth William Duncan, Michael John Munchhof
-
Publication number: 20220267260Abstract: The present invention provides compounds, pharmaceutically acceptable compositions thereof, and methods of using the same.Type: ApplicationFiled: November 29, 2017Publication date: August 25, 2022Inventor: Darren Martin Harvey
-
Publication number: 20220243454Abstract: An assembly for offsite construction of a building, a connector for use in such an assembly, along with a method of manufacture of such a connector, and a method of construction using the assembly. The connector includes first and second buttress elements defining, respectively, a first location portion and a second location portion. The first location portion and the second location portion are configured, respectively, to receive first and second structural elements extending at transverse angles to each other. The first and second buttress elements each has first and second opposite side walls defining an access space between them for a connector to be accessed. The second side wall of the first buttress element and the second side wall of the second buttress element together define a third location portion configured to receive a third structural element extending transversely to the first and second structural elements.Type: ApplicationFiled: July 9, 2020Publication date: August 4, 2022Inventors: David Clark, Anthony Illingsworth, Richard Crosby, James Cowell, Chris Hoggarth, Martin Harvey
-
Patent number: 11391099Abstract: An oilfield band cutter is useful for removing a band from a tubing string structure as the tubing string structure is being pulled up from the well. The oilfield band cutter includes a base frame with a central hole, an axis extending vertically and centrally through the frame coaxial with the central hole. A tubing follower member is coupled to the base frame and is positioned against an outer surface of the tubing string structure. A cutter is coupled to the tubing follower member, the cutter including an underside having a cutting edge. The cutting edge is positioned to engage against and cut bands on the tubing string structure.Type: GrantFiled: June 1, 2020Date of Patent: July 19, 2022Assignee: BAND SHARK CO. LTD.Inventors: Clayton Allan Jahn, Martin Harvey David Schmidt, Christopher Shaun Mcclelland, Stephen Joseph Hurst
-
Publication number: 20220162197Abstract: The present disclosure provides compounds, pharmaceutically acceptable compositions thereof, and methods of using the same.Type: ApplicationFiled: November 29, 2018Publication date: May 26, 2022Inventors: Darren Martin Harvey, John Emmerson Campbell, Kenneth William Duncan
-
Publication number: 20210215005Abstract: An oilfield band cutter is useful for removing a band from a tubing string structure as the tubing string structure is being pulled up from the well. The oilfield band cutter includes a base frame with a central hole, an axis extending vertically and centrally through the frame coaxial with the central hole. A tubing follower member is coupled to the base frame and is positioned against an outer surface of the tubing string structure. A cutter is coupled to the tubing follower member, the cutter including an underside having a cutting edge. The cutting edge is positioned to engage against and cut bands on the tubing string structure.Type: ApplicationFiled: June 1, 2020Publication date: July 15, 2021Inventors: CLAYTON ALLAN JAHN, MARTIN HARVEY DAVID SCHMIDT, CHRISTOPHER SHAUN McCLELLAND, STEPHEN JOSEPH HURST
-
Publication number: 20210198252Abstract: The present disclosure provides carboxamides and sulfonamides having Formula (I): and the pharmaceutically acceptable salts and solvates thereof, wherein A, Y, B, X, and Z are defined as set forth in the specification. The present disclosure is also directed to the use of compounds of Formula (I) to treat a disorder responsive to the blockade of SMYD proteins such a SMYD3 or SMYD2. Compounds of the present disclosure are especially useful for treating cancer.Type: ApplicationFiled: May 1, 2020Publication date: July 1, 2021Inventors: Megan Alene Cloonan Foley, Kevin Wayne KUNTZ, James Edward John MILLS, Lorna Helen MITCHELL, Michael John MUNCHHOF, Darren Martin HARVEY
-
Publication number: 20210198277Abstract: The present disclosure relates to amine-substituted aryl or heteroaryl compounds. The present disclosure also relates to pharmaceutical compositions containing these compounds and methods of treating a disorder (e.g., sickle cell anemia) via inhibition of a methyltransferase enzyme selected from EHMT1 and EHMT2, by administering an amine-substituted aryl or heteroaryl compound disclosed herein or a pharmaceutical composition thereof to subjects in need thereof. The present disclosure also relates to the use of such compounds for research or other non-therapeutic purposes.Type: ApplicationFiled: November 20, 2020Publication date: July 1, 2021Inventors: John Emmerson CAMPBELL, Kenneth William DUNCAN, Megan Alene FOLEY, Darren Martin HARVEY, Kevin Wayne KUNTZ, James Edward John MILLS, Michael John MUNCHHOF
-
Publication number: 20200148650Abstract: The present disclosure provides substituted isoxazole carboxamide compounds having Formula (1) and the pharmaceutically acceptable salts and solvates thereof, wherein R1, R2, A, X, and Z are defined as set forth in the specification. The present disclosure is also directed to the use of compounds of Formula I to treat a disorder responsive to the blockade of SMYD proteins such as SMYD3 or SMYD2 Compounds of the present disclosure are especially useful for treating cancer.Type: ApplicationFiled: September 30, 2019Publication date: May 14, 2020Inventors: Megan Alene Cloonan Foley, Kevin Wayne KUNTZ, James Edward John MILLS, Lorna Helen MITCHELL, Michael John MUNCHHOF, Darren Martin HARVEY
-
Publication number: 20200102314Abstract: The present disclosure provides substituted pyrrolidine compounds having Formula (I): and the pharmaceutically acceptable salts and solvates thereof, wherein R1, B, X, and Z are defined as set forth in the specification. The present disclosure is also directed to the use of compounds of Formula (I) to treat a disorder responsive to the blockade of SMYD proteins such as SMYD3 or SMYD2. Compounds of the present disclosure are especially useful for treating cancer.Type: ApplicationFiled: August 5, 2019Publication date: April 2, 2020Applicant: EPIZYME, INC.Inventors: Megan Alene Cloonan Foley, Kevin Wayne Kuntz, Lorna Helen Mitchell, Michael John Munchhof, Darren Martin Harvey
-
Publication number: 20200048195Abstract: The present disclosure provides pyrrolidine carboxamide compounds having Formula I and the pharmaceutically acceptable salts and solvates thereof, wherein A, B, X, Y, and Z are defined as set forth in the specification. The present disclosure is also directed to the use of compounds of Formula I to treat a disorder responsive to the blockade of SMYD proteins such as SMYD3 or SMYD2. Compounds of the present disclosure are especially useful for treating cancer.Type: ApplicationFiled: May 28, 2019Publication date: February 13, 2020Inventors: Megan Alene Cloonan Foley, Kevin Wayne KUNTZ, Lorna Helen MITCHELL, Michael John MUNCHHOF, Darren Martin HARVEY
-
Publication number: 20190322660Abstract: The present disclosure provides carboxamides and sulfonamides having Formula (I): and the pharmacentically acceptable salts and solvates thereof, wherein A, Y, B, X, and Z are defined as set forth in the specification. The present disclosure is also directed to the use of compounds of Formula (I) to treat a disorder responsive to the blockade of SMYD proteins such as SMYD3 or SMYD2. Compounds of the present disclosure are especially useful for treating cancer.Type: ApplicationFiled: February 6, 2019Publication date: October 24, 2019Inventors: Megan Alene Cloonan Foley, Kevin Wayne Kuntz, James Edward John Mills, Lorna Helen Mitchell, Michael John Munchhof, Darren Martin Harvey
-
Patent number: 10428029Abstract: The present disclosure provides substituted isoxazole carboxamide compounds having Formula (I) and the pharmaceutically acceptable salts and solvates thereof, wherein R1, R2, A, X, and Z are defined as set forth in the specification. The present disclosure is also directed to the use of compounds of Formula I to treat a disorder responsive to the blockade of SMYD proteins such as SMYD3 or SMYD2. Compounds of the present disclosure are especially useful for treating cancer.Type: GrantFiled: September 9, 2015Date of Patent: October 1, 2019Assignee: EPIZYME, INC.Inventors: Megan Alene Cloonan Foley, Kevin Wayne Kuntz, James Edward John Mills, Lorna Helen Mitchell, Michael John Munchhof, Darren Martin Harvey
-
Patent number: D983021Type: GrantFiled: January 13, 2021Date of Patent: April 11, 2023Assignees: Moonshine Investment Holdings Limited, Elliott Group Limited, McAvoy Modular Offsite LimitedInventors: Richard Crosby, James Cowell, Anthony Illingsworth, Chris Hoggarth, David Clark, Martin Harvey